In a preclinical study, adenovirus vector-delivered tumor neoantigen vaccine combined with anti-PD-1 antibodies significantly enhanced tumor immunogenic, neoantigen-specific CD8+ T-cell response and extended overall survival in MC38 tumor-bearing mice [62]. Here, CD8A is linked to neoplasm.